Skip to content

Looking for Bayesian expertise in India, for the purpose of analysis of sarcoma trials

Prakash Nayak writes:

I work as a musculoskeletal oncologist (surgeon) in Mumbai, India and am keen on sarcoma research.

Sarcomas are rare disorders, and conventional frequentist analysis falls short of providing meaningful results for clinical application.

I am thus keen on applying Bayesian analysis to a lot of trials performed with small numbers in this field.

I need advise from you for a good starting point for someone uninitiated in Bayesian analysis. What to read, what courses to take and is there a way I could collaborate with any local/international statisticians dealing with these methods.

I have attached a recent publication [Optimal timing of pulmonary metastasectomy – is a delayed operation beneficial or counterproductive?, by M. Kruger, J. D. Schmitto, B. Wiegmannn, T. K. Rajab, and A. Haverich] which is one amongst others I understand would benefit from some Bayesian analyses.

I have no idea who in India works in this area so I’m just putting this one out there in the hope that someone will be able to make the connection.


  1. Gautam Menon says:

    I would suggest R. Siddharthan ( as someone with a strong interest in Bayesian methods applied to several problems.

  2. Guru says:

    Prof. Rahul Siddharthan at Institute of Mathematical Sciences at Chennai might be the right contact person.

  3. We at Center for Translational Medicine (, University of Maryland would like to take this oppurtunity to discuss further and collaborate with you on this research question. Our faculty’s research also include designing and analyzing clinical trials by bayesian methodology.

  4. Kamakshaiah says:

    Possibly I may help you do analysis, interpretation and reporting. If you want to know about me more kindly visit

  5. K? O'Rourke says:

    > rare disorders, and conventional frequentist (and Bayesian) analysis falls short of providing meaningful results for clinical application

    There is a literature which should include “orphan drugs” that tries to purposefully indentify the challenges and issues of clinical research on rare disorders.

    The implicit thought that someone with conventional training in Bayesian statistics would likely contribute _without_ that background insight is misguided.

    My sense is that such statisticians are rare in Canada if not also US and Europe.

Leave a Reply